Flexibility Key for Bay Area Biotech Firms Seeking Space

🤝 There is nothing quite like having the whole team together in one room! This week we welcomed our US-based colleague, Senior Advisor Joe Rayne to the Munich office! At Trophic, we believe in taking the time to connect with one another while also making room for continuous learning. That's why this week we packed the schedule with a team breakfast and dinner, as well as a deep-dive training session on the business of biotech, focusing specifically on the intricacies of IPOs and the strategic journey of going public. Sharing and sharpening our expertise in capital markets is just one of the ways we ensure we are delivering the best strategic support to our life sciences clients. Below are a few moments from our time together! #TrophicCommunications #BiotechComms #TeamCulture

With the industry heading into a critical stretch leading up to major convenings, we’ll cut through the noise and focus on what matters most for investors, operators, and innovators, including the growing impact of cross-border dynamics. Join me, along with colleagues from McDermott Will & Schulte and EY-Parthenon as we discuss the current state of life sciences deal activity – and where momentum is (and isn’t) building: - Capital formation trends across biotech, MedTech, and emerging platforms - Strategic shifts in partnerships, licensing, and M&A - Regulatory, reimbursement, and policy dynamics impacting growth and exits - What to watch heading into the second half of the year I’m looking forward to this conversation. Register here: https://lnkd.in/gtFQwQVc

In our latest blog, Labshares CEO Philip Borden shares his perspective on where the biotech market is headed and what we're seeing firsthand across our community. We're hearing more conversations about hiring, expansion, and growth, and seeing encouraging signs that momentum is returning across the biotech ecosystem. Check out our latest blog, which includes a short clip from Philip's fireside chat with Nagib Charles at our Scaling Lab Operations event: https://lnkd.in/g5FDFQDW

At HYBRIDGE, we believe that innovation based on known molecules can only move forward when its value is properly assessed. Clear evaluation helps turn scientific potential into stronger development and business decisions. That is why Ana Gavaldá, PhD, Founder of HYBRIDGE and Annion PM Managing Partner, will join the Annual Conference 2026 to share her perspective on evaluating VAMs and 505(b)(2) products. Her session will explore the key elements that shape the value of these opportunities, helping participants approach assessment with greater structure and clarity. It will also highlight how a robust framework can support investment decisions, portfolio prioritization, and strategic planning across different stages of development. Because advancing known molecules requires more than identifying potential. It requires knowing how to prioritize, plan, and build the right path forward. Register now to join us in Barcelona on 16–17 September: https://lnkd.in/esQjkNyu #HYBRIDGE #PharmaInnovation #DrugDevelopment #HybridMedicines

A great reminder that experience, relationships and curiosity can open unexpected doors throughout a career. Check out Cooley LLP's interview with alum Matt Fleming now.

A great reminder that experience, relationships and curiosity can open unexpected doors throughout a career. Check out Cooley LLP's interview with alum Matt Fleming now.

Career paths are rarely linear – it's inspiring to see how different experiences can shape new opportunities and perspectives. Check out Cooley LLP's interview with alum Matt Fleming now.

Career paths are rarely linear – it's inspiring to see how different experiences can shape new opportunities and perspectives. Check out Cooley LLP's interview with alum Matt Fleming!

How do you go from being interested in longevity to building companies in the field? Our next webinar features Dr. Kelsey Moody, PhD, MBA, founder and CEO of Ichor Life Sciences, Inc., who has spent the past decade building one of the most unique companies in longevity biotech. We'll discuss: 🧬 His journey into longevity entrepreneurship 🤝 Partnerships, collaborations, and how biotech gets built 🔬 How contract research organizations (CROs) work alongside internal R&D 💬 Live audience Q&A At LongX, we believe that entering longevity shouldn't depend on where you're from, who you know, or whether you already have years of experience. Conversations like these are meant to make the field more accessible by giving aspiring scientists, founders, and builders the chance to learn directly from the people shaping it. Register here: https://luma.com/teggts01

For early-stage biotech founders, capital is only part of the equation. Access to specialist scientific expertise at the right moment can be just as important in generating the data, validating discoveries and reaching the next milestone. We're delighted to be working with o2h discovery to help give innovative life sciences companies access to additional technical support alongside investment. Looking forward to seeing how founders make the most of this opportunity and the breakthroughs it helps unlock.